Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer

ConditionPrimary Liver Cancer

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorTianjin Medical University Cancer Institute and Hospital

About this trial

A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Prior to implementing any trial-related procedures, written informed consent must be signed;

Age ≥ 18 years and ≤ 75 years;

Child-Pugh score ≤ 7;KPS score ≥ 70;

The patient must be clearly diagnosed with hepatocellular carcinoma, usually confirmed through imaging (CT, MRI) or histological examination (biopsy);

Disqualifiers

Possible surgical intervention;

Presence of other serious comorbidities, such as uncontrolled cardiovascular diseases, pulmonary diseases, or dysfunction of other organs, where the overall health status is poor and may result in treatment intolerance;

Severe liver dysfunction exceeding the specific criteria defined in the trial;

Other malignancies diagnosed within 5 years prior to the first treatment or at the time of diagnosis of hepatocellular carcinoma;

Trial design

Design model

Parallel

Treatments tested in this trial

Stereotactic Body Radiation Therapy (SBRT)
Procedure/Surgery
Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;
Radiofrequency ablation therapy
Procedure/Surgery
Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions

Treatment groups

130 Participants

are divided into 2 treatment groups

Group A: Stereotactic body radiation therapy groupExperimental treatment 1 intervention

Group B: Radiofrequency ablation therapy groupExperimental treatment 1 intervention